In the present study another ‘anti-/pro-tumor’ model defined by the CD8+ T lymphocyte/CD133+ CSC and CD8+ T lymphocyte/TB indices was used as an independent prognosis factor in patients with PDAC. The gene discussed is CD8A; the disease is neoplasm.